Stephens reiterated their equal weight rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research report report ...

Cidara Therapeutics (NASDAQ:CDTX – Get Free Report)‘s stock had its “overweight” rating restated by equities research ...

The upcoming Biotech Act will be part of the measures the Commission will target to turbo-charge investment and efficiency in ...

The need to harness and tap into numerous benefits of Genetically Modified Organisms (GMOS) has become paramount in the prevailing food insecurity being witness in the country. However, the battle for ...

It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...

Fidelity Advisor Biotechnology Fund earns an Above Average ... losses on some products in pursuit of broader strategic objectives. The firm is not without blemishes. Many of the active equity ...

As scientific discovery and technology advance, new opportunities arise and business priorities shift throughout the global ...

President Ursula von der Leyen presented the European Commission's plan to boost Europe's competitiveness and turn it into a place where future ...

The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology ...

The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology ...

Pull requests help you collaborate on code with other people. As pull requests are created, they’ll appear here in a searchable and filterable list. To get started, you should create a pull request.

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...